Vaxcyte Completes Phase 3 Enrollment for Pneumococcal Vaccine, Eyes 2026 Data
Event summary
- Vaxcyte completed enrollment for OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials evaluating VAX-31 for pneumococcal disease prevention in adults.
- Topline safety and immunogenicity data from OPUS-1 expected in Q4 2026, with OPUS-2 and OPUS-3 results due in early 2027.
- Company raised $632.5 million in February 2026, boosting cash reserves to $2.7 billion as of March 31, 2026.
- VAX-31 Phase 1/2 adult data published in The Lancet Infectious Diseases showed robust immune responses and safety profile.
- Vaxcyte plans to initiate Phase 1 study for VAX-A1, a Group A Strep vaccine, in mid-2026.
The big picture
Vaxcyte's completion of Phase 3 enrollment for VAX-31 marks a critical milestone in its quest to develop a best-in-class pneumococcal vaccine. The company's strong financial position, bolstered by recent fundraising, positions it well to navigate the complex regulatory landscape and scale manufacturing capabilities. The broader industry is watching closely as Vaxcyte aims to set a new standard for pneumococcal disease prevention, potentially expanding coverage and improving outcomes for both adults and infants.
What we're watching
- Regulatory Strategy
- Whether VAX-31's Phase 3 data will support a Biologics License Application submission and potential U.S. commercial launch.
- Execution Risk
- The pace at which Vaxcyte can advance VAX-A1 through clinical trials and manufacturing readiness.
- Market Positioning
- How VAX-31's expanded coverage against pneumococcal disease will compete with existing vaccines like Prevnar 20 and Capvaxive.
Related topics